Please assess the completion status of the following clinical trial:

Trial Title: Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients at least 18 years of age.~* Require a platelet count below 75 x 10\^9 /L at time of screening.~* The patients must meet the eligibility criteria for all drugs involved.~* Only genotype 1 (a, b, indeterminate, or mixed).~* Confirmed history of chronic hepatitis C.~* Cirrhotic patients will be included.~* Liver imaging within 1 year to exclude hepatocellular carcinoma (HCC) is required in patients with cirrhosis.~* Patients without evidence of cirrhosis but meeting platelet criteria will also be admitted to study.~* Subjects must be able to provide informed consent, comply with drug administration instructions, and be able to complete each study visit.~* Ability to cover costs of ribavirin, interferon, and boceprevir will also be required.~* Female subjects are eligible if: Non-pregnant, non-childbearing potential, or of childbearing potential and willing to perform complete abstinence or correctly use a form of birth control during intercourse \[barrier method, intrauterine device, hormonal therapy, or surgical sterilization in females or male partner\]. They must also be willing to have pregnancy tests performed every 4- weeks until 6 months after completion of ribavirin.~* Male study participants must agree to use a condom and their female partner must partake in one of the contraceptive methods discussed above until 6 months after completion of ribavirin therapy.~Exclusion Criteria:~* A history of chronic infection (i.e., HIV or HBV) or a previous organ transplantation.~* A history of a platelet disorder.~* A poorly controlled underlying medical illness (i.e., diabetes, hypertension, coronary artery disease, congestive heart failure, etc.).~* Any contraindication to any study drugs as mentioned in their respective prescribing information.~* Patients with decompensated cirrhosis defined as current evidence for ascites, encephalopathy, infection or variceal bleeding. All patients should be considered Child-Pugh Class A.~* Patients with aminotransferase levels ≥ 500 IU/L will be excluded on presumption of another active liver disease.~* Patients must not be pregnant or nursing.~* The study physician maintains the right to exclude a patient for a medical condition not listed above or based off laboratory values indicating chronic disease discovered at screening.~* Patients with eye disease may be excluded from this study if the ophthalmologist does not recommend treatment.~* Subjects with known hypersensitivity reactions (such as Stevens-Johnson syndrome, toxic, epidermal necrolysis, and erythema multiforme to ribavirin) to study drugs or any component of the products.~* Subjects with autoimmune hepatitis, hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia), creatinine clearance less than 50 mL/min.~* Co-administration of drugs that are highly dependent on CYP3A4/5 for clearance and CYP3A4/5 inducers (See Table 2 in boceprevir prescribing information).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Thrombocytopenic (Low Platelet) Patients (Type: EXPERIMENTAL): All study patients will undergo intervention in this study.~The intervention will be a lead-in with eltrombopag and antiviral triple therapy (interferon, ribavirin and boceprevir).

Based on this trial design, predict the completion outcome and termination type (if applicable).